摘要
目的探讨卵巢癌组织中沉默信息调节因子1(SIRT-1)、CD44表达的临床价值。方法收集116例卵巢癌患者的癌组织及切缘阴性>1 cm的癌旁组织,采用免疫组化法检测组织中SIRT-1、CD44的表达情况。同时收集所有患者的临床病理资料。采用Spearman等级相关分析评估SIRT-1与CD44的相关性。结果卵巢癌组织SIRT-1、CD44表达阳性率均显著高于癌旁组织(P<0.05)。组织学分级G1级、国际妇产科联合会(FIGO)分期Ⅲ~Ⅳ期、浸润度T3~T4期、有淋巴结转移的卵巢癌患者癌组织SIRT-1、CD44阳性率分别高于G2~G3级、Ⅰ~Ⅱ期、T1~T2期和无淋巴结转移的患者(P<0.05),不同年龄、病理类型和肿瘤直径患者SIRT-1、CD44阳性率差异均无统计学意义(P>0.05)。Spearman等级相关分析结果显示,卵巢癌组织SIRT-1表达与CD44表达呈正相关(r=0.721,P<0.001)。结论SIRT-1、CD44与卵巢癌发生、发展有关,或可作为评估卵巢癌患者病情的生物标志物。
Objective To investigate the expressions and clinical significance of silence information regulator-1(SIRT-1)and CD44 in ovarian cancer tissues.Methods The cancer tissues and adjacent tissues with positive resection margin>1 cm from 116 patients with ovarian cancer were collected,and the expressions of SIRT-1 and CD44 were determined by immunohistochemistry.The clinicopathological data of all the patients were collected.The correlation between SIRT-1 and CD44 was assessed by Spearman rank correlation analysis.Results The expression positive rates of SIRT-1 and CD44 in ovarian cancer tissues were higher than those in adjacent tissues(P<0.05).In the expression positive rates of SIRT-1 and CD44 in ovarian cancer tissues,there was no statistical significance in the different ages,disease types and tumor diameters(P>0.05),those of histological grade G1 were higher than those of G2-G3,those of the International Federation of Gynecology and Obstetrics(FIGO)stageⅢ-Ⅳwere higher than those ofⅠ-Ⅱ,those of the infiltration degree T3-T4 were higher than those of T1-T2,and those with lymph node metastasis were higher than those without lymph node metastasis(P<0.05).Spearman grade correlation analysis showed that SIRT-1 was positively correlated with CD44 expression in ovarian cancer tissues(r=0.721,P<0.001).Conclusions SIRT-1 and CD44 are related to the occurrence and development of ovarian cancer,or they can be the markers for the disease severity asseessment of ovarian cancer patients.
作者
刘蓉
王德刚
LIU Rong;WANG Degang(Department of Gynaecology,Lichuan People's Hospital,Lichuan 445400,Hubei,China)
出处
《检验医学》
CAS
2022年第7期632-635,共4页
Laboratory Medicine